ÓÉÒ×óҽÁÆÖ÷Àí£¬£¬£¬£¬£¬£¬Õ޼¯ÍÅ×÷Ϊ֧³Öµ¥Î»µÄ2024 IDCÐÂÒ©Ñз¢Ó°ÏìÁ¦´ó»á½«ÓÚ8ÔÂ8ÈÕÖÁ10ÈÕÔÚÉϺ£Õ޾ÙÐС£¡£¡£¡£¡£¡£±¾´Î´ó»á½«¾Û½¹ÉúÎïÒ½Ò©ÁìÓòµÄÇ°ÑØ»°Ì⣬£¬£¬£¬£¬£¬²¢½«Î§ÈÆÏ¸°û»ùÒòÖÎÁÆ¡¢ºËËáÒ©Îï¡¢ADCÒ©ÎïµÈÈÈÃÅзÖ×Ó»°Ì⿪չ¶à¸öƽÐÐÂÛ̳£¬£¬£¬£¬£¬£¬Íƶ¯Á¢ÒìÑз¢£¬£¬£¬£¬£¬£¬Í»ÆÆ¼¼ÊõÆ¿¾±£¬£¬£¬£¬£¬£¬Ôö½ø²úѧÑÐÉî¶ÈÈںϡ£¡£¡£¡£¡£¡£
ÃÀ¸ß÷Ê×ϯ¿ÆÑ§¹ÙÅíË«Çå½ÌÊÚ½«³öϯ´Ë´Î´ó»á£¬£¬£¬£¬£¬£¬²¢Ïòµ¼ÃÀ¸ß÷ÍŶӽ«ÔÚ¡¾Õ¹Î»ºÅ£ºS032¡¿È«³ÌÉèÕ¹£¬£¬£¬£¬£¬£¬³ÏÑûÄúݰÁÙÏÖ³¡½»Á÷£¡

¾Û»áʱ¼ä£º2024Äê8ÔÂ8ÈÕ-10ÈÕ
¾Û»áËùÔÚ£ºÉϺ£ÕŽ¿ÆÑ§ÀñÌÃ
£¨ÉϺ£ÊÐÆÖ¶«ÐÂÇøº£¿£¿£¿£¿£¿ÆÂ·1393ºÅ£©
ÃÀ¸ß÷չλºÅ£ºS032

ɨÂëÃâ·Ñ×¢²á

2024IDC×îÐÂÒé³Ì
´ó»áÔ¼ÇëÉÏǧλPharma¡¢BiotechÆóÒµCSOÓëÑз¢ÈÏÕæÈËͨ¹ýÖ÷Ìâ½²»°¡¢Ô²×ÀÌÖÂÛ¡¢±ÕÃÅ»áµÈÐÎʽ£¬£¬£¬£¬£¬£¬ÍÚ¾òÑз¢·çÏò±ê£¬£¬£¬£¬£¬£¬½á¹¹Ç°ÑعÜÏߣ»£»£»£»Í»ÆÆ¼¼ÊõÆ¿¾±£¬£¬£¬£¬£¬£¬Íƶ¯Á¢ÒìÑз¢¡£¡£¡£¡£¡£¡£
IDCÐÂÒ©Ñз¢Ó°ÏìÁ¦ÂÛ̳
<²¶»ñÑз¢·çÏò±ê£¬£¬£¬£¬£¬£¬Í»ÆÆ¼¼ÊõÆ¿¾±>
ÐÂÒ©Ñз¢ÒԿƼ¼Çý¶¯Á¢Ò죬£¬£¬£¬£¬£¬ÒýÁ쿵½¡Î´À´¡£¡£¡£¡£¡£¡£ÔÚÃæÁÙÈ«ÇòͬÖÊ»¯¾ºÕùµÄÇéÐÎÏ£¬£¬£¬£¬£¬£¬Á¢ÒìÄÜÁ¦ÊÇÆóÒµ½¹µã¾ºÕùÁ¦£¬£¬£¬£¬£¬£¬ÔõÑùÍ»ÆÆÄÚ¾í£¬£¬£¬£¬£¬£¬°ÎµÃÍ·³ïÒ²ÊÇËùÓпÆÑ§¼Ò×Î×β»¾ëÑо¿µÄÆ«Ïò¡£¡£¡£¡£¡£¡£±¾ÂÛ̳»ã¾ÛÈ«ÇòÐÂÒ©Ñз¢Èȵ㣬£¬£¬£¬£¬£¬º¸ÇÁ¢Òì°Ðµã¡¢¼¼ÊõÆ½Ì¨Í»ÆÆ¡¢Ç°Ñؼ¼ÊõÕ¹ÍûµÈ»°Ì⣬£¬£¬£¬£¬£¬Ô¼ÇëÒ©Æó¸ß²ã¡¢¿ÆÑнÌÊÚ¡¢ÁÙ´²×¨¼ÒÒÔ±¨¸æ¡¢Ô²×ÀÌÖÂÛµÈÐÎʽ·ÖÏíÆóÒµ×îÐÂÏ£Íû¡¢»ù´¡Ñо¿Í»ÆÆ¡¢ÎªÖª×ãÁÙ´²ÐèÇ󣬣¬£¬£¬£¬£¬¶à·½Ì½Ë÷ÐÂÒ©Ñз¢ÐÂÍ»ÆÆ¡£¡£¡£¡£¡£¡£
8ÔÂ9ÈÕÈ«Ì죨¿Æ´´Ìü£©
¡¾Í»ÆÆÄÚ¾í£¬£¬£¬£¬£¬£¬°Ðµã²î±ð»¯¿ª·¢²ßÂÔ¡¿
¡¾¿ª³¡¡¿ Ö÷³Ö£ºÏÄÃ÷µÂ£¬£¬£¬£¬£¬£¬¶Ê³¤¡¢Ê×ϯִÐй٣¬£¬£¬£¬£¬£¬Ó¢ÅµºþÒ½Ò©
Ö÷Ì⣺·Î°©¾«×¼ÖÎÁÆÌá¸ß»¼ÕßÉúÑÄÂÊ
¼Î±ö£ºÖܲʴ棬£¬£¬£¬£¬£¬Ö×Áö¿ÆÖ÷ÈΣ¬£¬£¬£¬£¬£¬Í¬¼Ã´óѧÁ¥Êô¶«·½Ò½Ôº
¶Ô»°£ºÔõÑù½«°©Ö¢ÖÎÁÆÏòÂý²¡¿´Æë£¿£¿£¿£¿£¿
¼Î±ö£ºÖܲʴ棬£¬£¬£¬£¬£¬Ö×Áö¿ÆÖ÷ÈΣ¬£¬£¬£¬£¬£¬Í¬¼Ã´óѧÁ¥Êô¶«·½Ò½Ôº
ÌÕά¿µ£¬£¬£¬£¬£¬£¬¸±×ܲüæÈ«ÇòÁ¢ÒìÒ©Ñз¢×Ü˾Àí£¬£¬£¬£¬£¬£¬ÆëÂ³ÖÆÒ©¼¯ÍÅ
¡¾ADC°Ðµã²î±ð»¯¿ª·¢×¨Ìâ¡¿
¡¾¿ª³¡¡¿ Ö÷³Ö£ºÏÄÃ÷µÂ£¬£¬£¬£¬£¬£¬¶Ê³¤¡¢Ê×ϯִÐй٣¬£¬£¬£¬£¬£¬Ó¢ÅµºþÒ½Ò©
Ö÷Ì⣺ÂõÍþÉúÎïADCÒ©Î↑·¢²ßÂÔ
¼Î±ö£ºÎ亣£¬£¬£¬£¬£¬£¬Ñз¢×ܲ㬣¬£¬£¬£¬£¬ÂõÍþÉúÎï
¡¾ÌáÒª¡¿£º
1. ÂõÍþÉúÎﶨµãżÁªADC¼¼Êõƽ̨IDDC
2. ÂõÍþÉúÎïADCҩѧºÍÉú²úƽ̨
3. ÂõÍþÉúÎïADC°ÐµãºÍÁÙ´²Ë³Ó¦Ö¢Ñ¡Ôñ
Ô²×ÀÌÖÂÛ£ºÈºÐÇÉÁׯ£¬£¬£¬£¬£¬£¬¾ßÓÐÈ«Çò¾ºÕùÁ¦µÄADCÒ©Îï²î±ð»¯¿ª·¢
Ö÷³Ö£ºÏÄÃ÷µÂ£¬£¬£¬£¬£¬£¬¶Ê³¤¡¢Ê×ϯִÐй٣¬£¬£¬£¬£¬£¬Ó¢ÅµºþÒ½Ò©
¼Î±ö£º²Ì¼ÒÇ¿£¬£¬£¬£¬£¬£¬ÁªºÏÊ×´´ÈË¡¢CSO £¬£¬£¬£¬£¬£¬ÒËÁªÉúÎï
ÖÜÓîºç£¬£¬£¬£¬£¬£¬CSO£¬£¬£¬£¬£¬£¬°ÙÁ¦Ë¾¿µ
Î亣£¬£¬£¬£¬£¬£¬Ñз¢×ܲ㬣¬£¬£¬£¬£¬ÂõÍþÉúÎï
¡¾ÄÑÒÔ³ÉÒ©°Ðµã¿ª·¢×¨Ìâ¡¿
Ö÷Ì⣺·Ö×Ó½ºÍ»ÆÆ¡°ÄÑÒÔ³ÉÒ©°Ðµã¡±×îÐÂÑз¢Ï£Íû
¼Î±ö£º×ÞÀöêÍ£¬£¬£¬£¬£¬£¬ÁªºÏÊ×´´È˼æÊ×ϯִÐй٣¬£¬£¬£¬£¬£¬´ï¸èÉúÎï
Ô²×ÀÌÖÂÛ£º¹¥¿Ë¡°ÄÑÒÔ³ÉÒ©°Ðµã¡±£¬£¬£¬£¬£¬£¬¿ªÆôÐÂÒ©Ñз¢ÐÂÕ÷³Ì
¼Î±ö£ºÀîÓÀ¹ú£¬£¬£¬£¬£¬£¬¶Ê³¤¡¢CSO£¬£¬£¬£¬£¬£¬¼ÎÔ½Ò½Ò©
×ÞÀöêÍ£¬£¬£¬£¬£¬£¬ÁªºÏÊ×´´È˼æÊ×ϯִÐй٣¬£¬£¬£¬£¬£¬´ï¸èÉúÎï
ӢΰÎÄ£¬£¬£¬£¬£¬£¬Ê×´´ÈË&CEO£¬£¬£¬£¬£¬£¬«zŵÉúÎï
¡¾¡°ºÏ³ÉÖÂËÀ¡±Ð°еãרÌâ¡¿
Ö÷³Ö£ºÀîÕýÌΣ¬£¬£¬£¬£¬£¬Ð¡·Ö×ÓÑз¢¸±×ܲ㬣¬£¬£¬£¬£¬ÏÈÉùÔÙÃ÷
Ö÷Ì⣺BRCAÍ»±äÈéÏÙ°©ÖÎÁÆÏ£Íû
¼Î±ö£º²ÜÎÄÃ÷£¬£¬£¬£¬£¬£¬Ö÷ÈΣ¬£¬£¬£¬£¬£¬Õã½Ê¡Ö×ÁöÒ½Ôº
¡¾ÌáÒª¡¿£º
1. BRCAÍ»±äÈéÏÙ°©Ê¢Ðв¡Ñ§
2. BRCAÍ»±äÈéÏÙ°©»¯ÁÆÏ£Íû
3. BRCAÒÖÖÆ¼ÁÖÎÁÆÏ£Íû
Ô²×ÀÌÖÂÛ£ºÖ×Áö°ÐÏòÒ©ÎïÖÎÁÆÏÂÒ»³Ç£¬£¬£¬£¬£¬£¬ºÏ³ÉÖÂËÀ¡±ÁÆ·¨ÐÂÍ»ÆÆ
Ö÷³Ö£ºÀîÕýÌΣ¬£¬£¬£¬£¬£¬Ð¡·Ö×ÓÑз¢¸±×ܲ㬣¬£¬£¬£¬£¬ÏÈÉùÔÙÃ÷
¼Î±ö£º²ÜÎÄÃ÷£¬£¬£¬£¬£¬£¬Ö÷ÈΣ¬£¬£¬£¬£¬£¬Õã½Ê¡Ö×ÁöÒ½Ôº
Ò°Í⣬£¬£¬£¬£¬£¬³£Îñ¸±×ܲá¢Ê×ϯ¿ÆÑ§¹Ù£¬£¬£¬£¬£¬£¬Ó¢ÅÉÒ©Òµ
¡¾Ï¸°ûÖÎÁÆÊµÌåÁöÍ»ÆÆ×¨Ìâ¡¿
Ö÷Ì⣺ϸ°ûÖÎÁÆÔÚʵÌåÁöÒ©Î↑·¢ÖаеãÑ¡Ôñ
¼Î±ö£ºÇ®³Ì£¬£¬£¬£¬£¬£¬¶Ê³¤¡¢Ê×ϯ¿ÆÑ§¼Ò£¬£¬£¬£¬£¬£¬¾«×¼ÉúÎï
Ô²×ÀÌÖÂÛ£ºÏ¸°ûÖÎÁÆ´ÓѪҺÁöµ½ÊµÌåÁöÍØÕ¹ÖÐÑз¢¼¼ÊõÍ»ÆÆ
Ö÷³Ö£ºÉòºÆ£¬£¬£¬£¬£¬£¬CSO£¬£¬£¬£¬£¬£¬¸´ÐÇ¿ÌØ
¼Î±ö£ºº«ÑÐåû£¬£¬£¬£¬£¬£¬¸±×Ü˾Àí£¬£¬£¬£¬£¬£¬ºãÈðÔ´Õý
ÉòÁ¬¾ü£¬£¬£¬£¬£¬£¬¸ß¼¶¸±×ܲá¢Ñз¢ÈÏÕæÈË£¬£¬£¬£¬£¬£¬Ø¨Ï²ÉúÎï
Ç®³Ì£¬£¬£¬£¬£¬£¬¶Ê³¤¡¢Ê×ϯ¿ÆÑ§¼Ò£¬£¬£¬£¬£¬£¬¾«×¼ÉúÎï
¡¾ºËËØÒ©ÎïаеãרÌâ¡¿
Ö÷Ì⣺225Ac-FL-020-a novel PSMA-targeting radioligand therapy candidate in development
¼Î±ö£ºÁõ·¢£¬£¬£¬£¬£¬£¬CSO£¬£¬£¬£¬£¬£¬·øÁª¿Æ¼¼
¡¾ÌáÒª¡¿£ºRadioligand therapy (RLT) has recently demonstrated attractive clinical benefits. Such early success has promoted the race for next wave RLTs where exciting opportunities and unique challenges have been both presented. Here we will disclose the discovery of 225Ac-FL-020, a novel PSMA-targeting RLT candidate identified by our proprietary Clear-X technology platform.
Ô²×ÀÌÖÂÛ£ºÒ©ÎïÑз¢µÄмÍÔª£¬£¬£¬£¬£¬£¬ºËËØÒ©Î↑·¢ÖеĻúÔµÓëÌôÕ½
¼Î±ö£ºÁõ·¢£¬£¬£¬£¬£¬£¬CSO£¬£¬£¬£¬£¬£¬·øÁª¿Æ¼¼
¹ù·É»¢£¬£¬£¬£¬£¬£¬×Ü˾Àí£¬£¬£¬£¬£¬£¬Ìì½òºãÈðÒ½Ò©ÓÐÏÞ¹«Ë¾
³ÌÕ𣬣¬£¬£¬£¬£¬Ñо¿Ô±£¬£¬£¬£¬£¬£¬Öйú¿ÆÑ§ÔºÉϺ£Ò©ÎïÑо¿Ëù
¸ü¶àÂÛ̳Òé³ÌÏê¼û>>
¸÷ÂÛ̳ʱ¼ä¼°ËùÔÚÐû²¼£¡2024IDCµÚÈý½ìÐÂÒ©Ñз¢Ó°ÏìÁ¦´ó»á
¹ØÓÚÃÀ¸ß÷
ÃÀ¸ß÷£¨¹ÉƱ´úÂ룺688202.SH£©½¨ÉèÓÚ2004Ä꣬£¬£¬£¬£¬£¬×ܲ¿Î»ÓÚÉϺ££¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚΪȫÇòÖÆÒ©ÆóÒµ¡¢Ñо¿»ú¹¹¼°¿ÆÑÐÊÂÇéÕßÌṩȫ·½Î»µÄÁÙ´²Ç°ÐÂÒ©Ñо¿Ð§ÀÍ¡£¡£¡£¡£¡£¡£ÃÀ¸ß÷µÄһվʽ×ÛºÏЧÀÍÒÔÇ¿ÓÐÁ¦µÄÏîÄ¿¹ÜÀíºÍ¸ü¸ßЧ¡¢¸ßÐԼ۱ȵÄÑз¢Ð§ÀÍÖúÁ¦¿Í»§¼ÓËÙÐÂÒ©Ñз¢Àú³Ì£¬£¬£¬£¬£¬£¬Ð§Àͺ¸ÇÒ½Ò©ÁÙ´²Ç°ÐÂÒ©Ñо¿µÄÈ«Àú³Ì£¬£¬£¬£¬£¬£¬°üÀ¨Ò©Îï·¢Ã÷¡¢Ò©Ñ§Ñо¿¼°ÁÙ´²Ç°Ñо¿¡£¡£¡£¡£¡£¡£ÖÁ2024Äê4ÔÂ⣬£¬£¬£¬£¬£¬ÃÀ¸ß÷ÒÑΪȫÇò³¬2000¼Ò¿Í»§ÌṩҩÎïÑз¢Ð§ÀÍ£¬£¬£¬£¬£¬£¬¼ÓÈëÑз¢Íê³ÉµÄÐÂÒ©¼°·ÂÖÆÒ©ÏîÄ¿ÒÑÓÐ480¼þIND»ñÅúÁÙ´²£¬£¬£¬£¬£¬£¬Ó뺣ÄÚÍâÓÅÖʿͻ§ÅäºÏÉú³¤¡£¡£¡£¡£¡£¡£ÃÀ¸ß÷½«¼ÌÐø×¤×ãÈ«ÇòÊÓÒ°£¬£¬£¬£¬£¬£¬¾ÛÁ¦ÖйúÁ¢Ò죬£¬£¬£¬£¬£¬ÎªÈËÀ࿵½¡Ð¢Ë³ÊµÁ¦£¡
ÁªÏµÃÀ¸ß÷